The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
The GLOW Stack is the Wolverine Stack with GHK-Cu added. Understanding why GHK-Cu is added — what it contributes that BPC-157 and TB-500 do not — is the foundation of this chapter.
The Wolverine Stack (BPC-157 + TB-500) addresses healing through two mechanisms: local angiogenesis and growth factor signaling at the injury site (BPC-157), and systemic progenitor cell mobilization to supply the cellular workforce for repair (TB-500). These two mechanisms together cover the primary bottlenecks in acute tissue repair. What they do not primarily address: the quality and organization of the extracellular matrix (ECM) being laid down during the repair process, and the cosmetic/aesthetic dimension of healing — how skin and connective tissue look and function long after the acute injury has resolved.
GHK-Cu adds the ECM remodeling layer. The copper tripeptide's mechanism — stimulating both matrix metalloproteinases (which remove damaged, disorganized collagen) and their tissue inhibitors (which prevent excessive breakdown), while simultaneously stimulating new collagen and elastin synthesis — produces organized, high-quality ECM rather than simply more collagen mass. The distinction matters clinically: scar tissue that forms rapidly but in a disorganized pattern (type III collagen, random fiber orientation) is mechanically inferior to organized type I collagen with aligned fiber architecture. GHK-Cu's MMP/TIMP regulation promotes the remodeling from disorganized repair tissue toward organized, functional tissue.
The cosmetic dimension: GHK-Cu's established topical evidence (8+ human RCTs; see GHK-Cu Topical chapter) and its systemic effects on collagen gene expression make it the stack's skin quality and anti-aging component. BPC-157 and TB-500 heal the tissue; GHK-Cu remodels and rejuvenates it. This is why 'GLOW' was chosen as the name — it captures both the skin quality dimension and the broader sense of systemic tissue renewal that the three-component stack targets.
THE CENTRAL TENSION
The GLOW Stack adds GHK-Cu's copper-mediated collagen remodeling to the Wolverine healing foundation — a mechanistically logical addition that addresses what Wolverine doesn't: ECM organization and cosmetic tissue quality. The tension: adding GHK-Cu adds the injectable copper safety considerations (active malignancy hard stop, Wilson disease contraindication, copper accumulation risk on long cycles) to the stack's risk profile. The active malignancy hard stop for GHK-Cu applies to the entire GLOW Stack — the other two components have a 'caution' signal for malignancy, but GHK-Cu elevates the whole stack to a hard stop. Additionally, the blended vial format (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500) fixes the 5:1:1 ratio regardless of individual dosing preferences — understanding when this ratio is appropriate and when separate vials are better is the practical core of this chapter.
Parameter
Blended 70mg Vial Protocol
Vial
70mg lyophilized (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500)
Reconstitution
3 mL bacteriostatic water; gentle swirl; expect blue tint
Daily dose
0.10 mL (10 units U-100) = 1.67mg GHK-Cu + 0.33mg BPC-157 + 0.33mg TB-500
Injection site
SubQ abdomen or thigh; rotate sites
Injection time
Evening/before bed (community convention)
Cycle
8-12 weeks for full dual-timeline benefit; 30-day rest minimum post-cycle
Monitoring
Serum copper + ceruloplasmin at baseline and week 8; ISR assessment; liver panel before starting
Component
Separate-Vial Dose
Frequency
Rationale for Separate
GHK-Cu (injectable)
1 mg/day (days 1-15); 2 mg/day (days 16-30)
Daily SubQ abdomen
Anela Protocol dose escalation; copper accumulation more precisely controlled
BPC-157
250-500 mcg/day SubQ
Daily; near injury site for musculoskeletal
Full therapeutic dose for musculoskeletal healing; blended vial underdelivers at 0.33mg/day
TB-500
5 mg/week loading (2.5mg × 2) × 4 weeks; then 2-5 mg/week maintenance
Twice weekly SubQ anywhere
Proper loading phase for systemic cell pool; blended vial cannot provide this pattern
When to use separate vials: (1) acute or severe musculoskeletal injury where BPC-157 and TB-500 dosing at full Wolverine doses matters most; (2) users who want precise GHK-Cu dose escalation per the Anela Protocol; (3) users where one component needs to be stopped independently (e.g., injury healed, continuing GHK-Cu for cosmetic benefit only). When the blended vial is preferred: (1) convenience-priority users; (2) chronic maintenance or cosmetic-primary use where precise dose control is less critical; (3) cost optimization (blended vials typically less expensive per mg than three separate vials).
Component
Role in GLOW
Individual Chapter
Key Safety
GHK-Cu (injectable, 50mg)
ECM remodeling: MMP/TIMP balance (removes damaged collagen, stimulates organized new collagen + elastin); >1,500 gene modulation; systemic healing enhancement (animal); skin quality and cosmetic dimension
C (animal systemic healing); E (community injectable); B (topical only)
GHK-Cu (Injectable)
Active malignancy: hard stop. Wilson disease: absolute contraindication. Copper accumulation monitoring on long cycles.
BPC-157 (10mg)
Local angiogenesis: VEGF upregulation, capillary growth at injury site; growth hormone receptor expression ↑; FAK fibroblast migration; gut protection
C (animal); E (community)
BPC-157
Active malignancy: caution. Category 1 FDA status; 503B compounding removed 2024.
TB-500 (10mg)
Systemic cell mobilization: actin polymerization, progenitor and endothelial cell trafficking to injury; NF-kB anti-inflammatory
C (parent compound animal); E (fragment community)
TB-500
Active malignancy: caution. No human RCT for TB-500 fragment specifically.
The 5:1:1 ratio (GHK-Cu:TB-500:BPC-157) is the market-standard blended vial configuration. Its origin is community-empirical rather than pharmacokinetically derived. The higher GHK-Cu proportion reflects: (1) GHK-Cu's significantly higher molecular weight (~408 Da vs ~1419 Da for BPC-157 and ~799 Da for TB-500) and lower per-mg potency relative to the other two compounds in absolute terms — effective GHK-Cu doses are typically 1-2 mg/day, while effective BPC-157 doses are 250-500 mcg/day; the molar ratio in the blended vial is therefore closer to parity than the mg ratio suggests; (2) community-developed sense that GHK-Cu requires a meaningful supply to produce the collagen remodeling effect over an 8-12 week timeline; and (3) the 50mg GHK-Cu in a 70mg vial provides approximately 30 days of 1.7mg/day GHK-Cu dosing if the vial is dosed daily — approximately matching the Anela Protocol's Phase 1 dosing.
The GLOW Stack's 70mg blended vial has a characteristic that no other peptide blend shares: the reconstituted solution turns blue. This is the GHK-Cu copper complex making itself visible, and it is a positive identity marker.
Standard GLOW blend reconstitution: 70mg lyophilized powder (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500) in one vial. Add 3 mL bacteriostatic water (BAC water). This produces a total concentration of approximately 23.3 mg/mL (16.7 mg/mL GHK-Cu + 3.3 mg/mL BPC-157 + 3.3 mg/mL TB-500). Reconstitution technique: inject BAC water slowly down the inside wall of the vial — do not aim the stream directly onto the powder, which can denature peptides; do not shake; gently swirl or roll until fully dissolved. The solution will develop a blue tint as the GHK-Cu copper complex dissolves — this is expected, confirms the presence of GHK-Cu, and is not a degradation indicator.
THE BLUE TINT — IDENTITY MARKER, NOT DEGRADATION
Reconstituted GLOW blend is distinctively blue. This is the copper (Cu²⁺) ion in GHK-Cu forming its characteristic blue coordination complex in solution. It is the same chemistry that makes copper sulfate solutions blue. A clear, colorless GLOW blend solution after reconstitution is a red flag — it may indicate absent or degraded GHK-Cu. A blue solution is the correct expected appearance. The depth of blue correlates roughly with GHK-Cu concentration. This is one of the most useful visual identity checks in the peptide blend market — use it.
Daily Injection Volume
GHK-Cu/injection
BPC-157/injection
TB-500/injection
Approximate Days from One Vial
0.06 mL (6 units U-100)
1.0 mg
0.2 mg
0.2 mg
~50 days
0.10 mL (10 units U-100)
1.67 mg
0.33 mg
0.33 mg
~30 days
0.12 mL (12 units U-100)
2.0 mg
0.4 mg
0.4 mg
~25 days
Important dose caveat: the 70mg blended vial at daily dosing provides adequate GHK-Cu (~1.7 mg/day) but suboptimal BPC-157 (~0.33 mg/day) relative to the standard Wolverine BPC-157 dose of 250-500 mcg/day — and provides only 0.33 mg/day TB-500, well below the 2-5 mg/week maintenance dose for TB-500 (~0.3-0.7 mg/day). The blended vial format compresses all three compounds into one injection but imposes dose constraints that may underdeliver BPC-157 and TB-500 relative to the separate-vial Wolverine protocol. Users prioritizing maximum healing (musculoskeletal injury) may find the separate-vial approach gives better control over BPC-157 and TB-500 dosing; users prioritizing the combined healing + cosmetic profile may prefer the blended vial convenience.
The three components of the GLOW Stack address different phases of the healing and remodeling cascade. Understanding the timeline is essential for setting realistic expectations and for choosing cycle length.
Timeline
Primary Active Component
What Is Happening
What to Expect
Days 1-7
BPC-157
Immediate: local VEGF upregulation, new capillary growth beginning at injury site; GHR expression increasing; NF-kB anti-inflammatory reducing local swelling
Reduced acute pain and inflammation; improved tissue perfusion at injury site; often the first subjective effect users notice
Days 7-21
BPC-157 + TB-500
Cell migration phase: TB-500 mobilizing systemic progenitor and endothelial cells; BPC-157 maintaining angiogenic environment; collagen deposition beginning
Subjective pain reduction, improved mobility, early structural improvement; most Wolverine-type effects observable by week 3
Weeks 3-6
All three active
GHK-Cu collagen remodeling underway: MMP-mediated removal of disorganized repair collagen, new organized type I collagen deposition, elastin synthesis; continued BPC-157 signaling and TB-500 systemic support
Tissue quality improving; early cosmetic skin effects beginning; structural healing consolidating
Weeks 6-12
GHK-Cu dominant (ongoing)
Deep collagen remodeling: dermis and connective tissue thickening; organized fiber architecture developing; gene expression changes propagating across >1,500 target genes
Visible skin quality improvement; connective tissue elasticity; full cosmetic and structural remodeling benefit; most significant GHK-Cu effect visible at weeks 8-12
The dual-timeline problem: if a user runs the GLOW Stack for only 4 weeks (common Wolverine cycle length), they will experience the BPC-157 and TB-500 healing benefits but will not have completed the GHK-Cu remodeling cycle. The minimum recommended GLOW Stack cycle is 8 weeks. For skin and cosmetic objectives, 12 weeks produces the most complete GHK-Cu effect. This longer cycle increases cumulative copper exposure — monitoring protocol (serum copper, ceruloplasmin) becomes more important at 8-12 week cycle lengths.
ACTIVE MALIGNANCY — HARD STOP FOR THE ENTIRE GLOW STACK
GHK-Cu's VEGF angiogenic mechanism is a hard stop for active malignancy — this is the strongest contraindication signal in the GHK-Cu Injectable chapter. BPC-157 and TB-500 individually carry 'caution' signals for malignancy (angiogenic and progenitor cell mobilization effects). Adding GHK-Cu elevates the entire GLOW Stack to a hard stop. No component of the GLOW Stack should be used in the presence of active malignancy. Physician consultation is mandatory for any cancer history, even in remission.
Wilson disease (ATP7B mutation) is an absolute contraindication for GHK-Cu and therefore for the entire GLOW Stack. The copper delivery mechanism that makes GHK-Cu therapeutically interesting is harmful in the context of impaired copper metabolism. Any patient with documented or suspected Wilson disease must not use the GLOW Stack.
The GLOW Stack's 8-12 week recommended cycle at daily GHK-Cu dosing (1.67-2 mg/day from blended vial) delivers approximately 14-21 mg of copper from GHK-Cu over the full cycle. This is within the tolerable upper intake range (10 mg/day UL × cycle days, though cumulative day-over-day body load depends on clearance) but warrants monitoring. The monitoring protocol: serum copper and ceruloplasmin at baseline before starting; recheck at week 8; liver function panel (ALT/AST) before starting. Elevated trending copper across successive cycles indicates accumulation — pause the protocol.
BPC-157 was designated Category 1 by the FDA and has been prohibited from compounding as a bulk drug substance. TB-500 was similarly removed from 503B bulk compounding eligibility in 2024. GHK-Cu has clearer compounding pharmacy access (FDA-approved drugs Factrel and Lutrepulse provide a regulatory foundation for compounded GHK-Cu formulations). The practical result: the GLOW Stack as a blended preparation from a 503B compounding pharmacy is not currently available through that regulatory channel for BPC-157 and TB-500. The blended vials widely available through research peptide vendors operate under the 'research purposes only' framework — not pharmaceutical compounding. Individuals seeking physician-supervised GLOW Stack access through clinics typically receive the components as separate 503A patient-specific prescriptions where available, or through research channels.
Pure acute musculoskeletal injury with no cosmetic or skin quality goals, time-sensitive recovery where a 4-week cycle is sufficient, users with cost constraints (GHK-Cu adds ~$30-60 per cycle), or users who want maximum BPC-157 and TB-500 dosing without the GHK-Cu copper considerations. For these users the Wolverine Stack (BPC-157 + TB-500) remains the appropriate choice — the GLOW Stack is not universally superior; it is a different protocol for a different primary objective.
Stack
Slug
Relationship to GLOW
Wolverine Stack
wolverine-stack
The subset: BPC-157 + TB-500 without GHK-Cu. Use when cosmetic/ECM remodeling layer is not needed, or when 4-week cycles are sufficient, or to avoid copper considerations.
KLOW Stack
klow-stack
The extension: GLOW + KPV. Adds KPV (Lys-Pro-Val, anti-inflammatory alpha-MSH tripeptide) for gut protection and enhanced systemic anti-inflammatory coverage. The most comprehensive healing + cosmetic + anti-inflammatory protocol.
GH Stack
gh-stack
Separate indication. CJC-1295 + Ipamorelin for GH axis stimulation. Occasionally combined with GLOW for comprehensive recovery protocols in performance contexts, but different mechanism entirely.
Fountain of Youth Stack
fountain-of-youth-stack
Shares GHK-Cu. Epitalon + GHK-Cu for longevity-focused protocols. The longevity version of the GHK-Cu application vs the GLOW healing/cosmetic version.
Format
Approximate Cost
Duration
Notes
70mg GLOW blended vial
$80-150 per vial
~30 days at 10 units/day
Most common format; blue tint in solution = correct; verify HPLC + mass spec COA
Full 8-week GLOW cycle (blended)
$200-350
One cycle
Two to three 70mg vials; highly variable by vendor quality
Full 8-week GLOW cycle (separate vials)
$250-500
One cycle
Higher cost; better dose control; recommended for acute injury protocols
Clinic/physician-supervised
$600-1500+
One cycle
Pharmaceutical-grade preparation; consultation; monitoring included
Quality verification for GLOW blends: HPLC purity for each component; mass spectrometry confirmation of all three molecular identities (MW: GHK-Cu ~408 Da, BPC-157 ~1419 Da, TB-500 ~799 Da); endotoxin (LAL) test for injectable-grade; batch-specific COA. The blue tint after reconstitution is a useful field identity check for GHK-Cu presence. A colorless GLOW blend or one that reconstitutes without any blue color is a sourcing concern.
See individual compound chapters for full references: GHK-Cu (Injectable), BPC-157, TB-500. Stack-specific literature: no published combination studies for the GLOW Stack as of mid-2026.
Campbell J. (2025). GLOW Peptide Protocol: BPC-157, TB-500 & GHK-Cu. jaycampbell.com. [Community originator documentation; 5:1:1 ratio rationale; SubQ protocol; the foundational community-facing GLOW Stack protocol.]
Moonshot Medical (2026). Glow Stack (GHK-Cu + BPC-157 + TB-500). moonshotmp.com. [Clinic-facing GLOW Stack documentation; dual timeline (1-3 weeks healing, 4-8 weeks cosmetic); 8-12 week full benefit; microneedling and cosmetic procedure recovery applications.]
Vasireddi N et al. (2025). BPC-157 systematic review. HSS Journal. [35 preclinical + 1 clinical BPC-157 study; Level IV-V human evidence; no combination studies for any BPC-157 stack.]
The GLOW Stack is the Wolverine Stack with a third mechanism added — collagen matrix remodeling — and a second application dimension added: cosmetic skin rejuvenation. It is more complex, requires longer cycles, and adds the GHK-Cu copper safety profile to the stack. It is not always the better choice over Wolverine — it is the right choice when both healing and tissue quality matter.
The mechanistic logic of GLOW is the clearest of any Tier 1 stack: three compounds, three non-overlapping mechanisms (local angiogenesis + systemic cell mobilization + ECM remodeling), two timelines (healing at weeks 1-3, collagen remodeling at weeks 6-12). The blended 70mg vial is a practical and well-designed format that makes the protocol accessible, though it imposes dose constraints that matter for users prioritizing maximum acute healing. The active malignancy hard stop from GHK-Cu applies to the whole stack. The copper monitoring protocol is essential for 8+ week cycles. The blue tint is an identity marker, not a problem. The dual timeline is the most important expectation-management issue: do not assess GLOW Stack results at 4 weeks if the goal includes the GHK-Cu cosmetic effect.
STACK SUMMARY
GLOW Stack: type=stack; slug=glow-stack; stackGrade=C. COMPONENTS: ghk-cu-injectable + bpc-157 + tb-500. relatedStacks: wolverine-stack (subset), klow-stack (extension), fountain-of-youth-stack (shares GHK-Cu). indication: full-spectrum healing + cosmetic tissue rejuvenation; musculoskeletal + skin + ECM remodeling. studyCounts: humanRct: 0, humanObs: 3, animal: 60+, inVitro: 40+, combinationStudies: 0. STANDARD BLENDED VIAL: 70mg = 50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 (5:1:1 ratio); reconstitute 3mL BAC water; BLUE TINT = correct (copper complex); colorless after reconstitution = concern. DOSE (blended vial): 0.10mL (10 units U-100) = 1.67mg GHK-Cu + 0.33mg BPC-157 + 0.33mg TB-500/day; ~30 days per vial. DOSE (separate vials, preferred for acute injury): GHK-Cu Anela Protocol (1mg → 2mg/day); BPC-157 250-500 mcg/day; TB-500 5mg/week loading → 2-5mg/week maintenance. DUAL TIMELINE: BPC-157 + TB-500 effects 1-3 weeks; GHK-Cu collagen remodeling 4-8 weeks; full GLOW benefit 8-12 weeks. MINIMUM CYCLE: 8 weeks. REST: 30+ days. MECHANISM LAYERS: BPC-157 = local angiogenesis (VEGF, GHR, FAK migration); TB-500 = systemic progenitor/endothelial mobilization (actin polymerization); GHK-Cu = ECM remodeling (MMP/TIMP, collagen/elastin, >1,500 gene expression). ACTIVE MALIGNANCY: HARD STOP (GHK-Cu angiogenic mechanism elevates entire stack). WILSON DISEASE: absolute contraindication (GHK-Cu copper delivery). COPPER MONITORING: serum copper + ceruloplasmin at baseline and week 8; liver panel before starting; essential for 8+ week cycles. REGULATORY: BPC-157 Category 1 FDA; TB-500 removed from 503B compounding 2024; GHK-Cu more stable access via 503A. COST: ~$200-350 per 8-week cycle (research grade blended vials). BLUE TINT is GHK-Cu copper complex — identity marker, not degradation. COMMON MISTAKES: 4-week cycle (misses GHK-Cu timeline); colorless solution alarm (blue is correct); blended vial underdoses BPC-157 for acute injury; skipping copper monitoring; shaking vial during reconstitution.
— End of GLOW Stack —
THE PEPTIDE BIBLE | GLOW Stack | For Research & Educational Purposes Only
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.